|Bid||0.00 x 1000|
|Ask||0.00 x 1000|
|Day's range||48.07 - 53.72|
|52-week range||6.70 - 146.16|
|Beta (5Y monthly)||0.51|
|PE ratio (TTM)||N/A|
|Earnings date||10 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||13 Dec 2012|
|1y target est||159.25|
Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.
Biogen's (BIIB) regulatory application seeking approval for its Alzheimer's drug, Aduhelm, in Europe hits setback as it receives negative trend vote from the CHMP.
Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.